Intravitreal Dexamethasone vs Bevacizumab in Aboriginal People With DMO
Status:
Completed
Trial end date:
2020-02-14
Target enrollment:
Participant gender:
Summary
DMO is the most common cause of visual loss in people with diabetes. Regular injections of
bevacizumab (Avastin) given as frequently as every month remain the current standard of care
for centre-involving DMO; however, this regimen is impractical for many Aboriginal patients.
Using Ozurdex implants every 3-6 months could be as effective as the currently used Avastin
injections. In order to address this real-world problem, this study seeks to investigate
whether it is possible to safely use a long-acting steroid preparation such as the
dexamethasone IVT implant (Ozurdex) to manage DMO in Aboriginal patients living in Western
Australia.